冠心内解剖/血液瘤的干预管理:综合性审查
Federico Giannino1, Gabriele Carciotto1, Francesco Pallante1
1Department of Clinical and Experimental Medicine, University of Messina, Messina, 98122, Italy.
Current cardiology reports
|June 3, 2025
概括
导致急性冠状动脉综合征的冠状动脉内解剖和血液瘤需要量身定制的管理. 先进的成像指导决策,与保守的,穿皮冠状动脉干预 (PCI),或根据患者的稳定性和解剖选择的手术选择.
科学领域:
- 心脏病学 心脏病学
- 血管医学 血管医学
- 干预心脏病学 干预心脏病学
背景情况:
- 冠状动脉内解剖和血液瘤是急性冠状动脉综合征 (ACS) 的不常见但严重的原因.
- 这些情况可能导致心肌缺血和心脏病发作,呈现出各种临床症状.
- 最佳的管理策略仍未完全定义,需要对当前的方法进行审查.
研究的目的:
- 评估当前治疗冠状动脉内解剖和血液瘤的治疗策略.
- 审查保守的,穿皮冠状动脉干预 (PCI) 和外科手术管理选项.
- 突出新兴的创新和未来的研究方向在管理这些条件.
主要方法:
- 关于冠状动脉内解剖和血液瘤管理的最新研究和文献的综述.
- 在诊断和治疗指导中强调先进的冠心内成像 (OCT,IVUS) 的作用.
- 分析与保守性,PCI和手术干预相关的结果.
主要成果:
- 先进的冠心内成像 (OCT,IVUS) 提高了诊断的准确性,并指导治疗.
- 保守的治疗对稳定的患者有效,具有有利的长期结果.
- PCI适用于正在进行的缺血或不稳定,而手术对于PCI失败或左主干涉至关重要.
结论:
- 量身定制的治疗策略,由成像和患者因素来告知,优化结果.
- 保守的管理适合选定的病例;PCI和手术对高风险患者至关重要.
- 未来的研究应该完善风险分层,成像和治疗算法,以便更好地照顾患者.
相关概念视频
Acute Coronary Syndrome IV: Interprofessional Care
337
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
337
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
553
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
553
Venous Thrombosis III: Interprofessional Care
410
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
410
Coronary Artery Disease V: Interprofessional Care
343
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343
Aneurysm III: Interprofessional Care
387
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
387
Angina IV: Management
359
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
359


